Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 0.97 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.80 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.80 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylatropine SCHEMBL34463463 | 1.00 | CHRM2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL1321572 | 0.99 | BLM (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL30647266 | 0.99 | BLM (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL29389879 | 0.99 | PABPC1 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL30003811 | 0.94 | SMN1; SMN2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL20798247 | 0.94 | SMN1; SMN2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Methylatropine SCHEMBL56394 | 0.94 | SMN1; SMN2 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Atropine Oxide SCHEMBL98985 | 0.90 | CYP2C19 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Atropine Oxide SCHEMBL29369999 | 0.90 | CYP2C19 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 | |
| Atropine Oxide SCHEMBL162929 | 0.90 | CYP2C19 (1.00) | CHRM2BLMPABPC1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523944-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-11-21 | — | — | EP | claimed |
| EP-2403340-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-01-11 | — | — | EP | claimed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | claimed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| EP-1438001-A4 | COMPOSITIONS AND METHODS FOR INHIBITING ECCRINE PERSPIRATION IN HUMANS | LUKACSKO ALISON B (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1438001-A2 | COMPOSITIONS AND METHODS FOR INHIBITING ECCRINE PERSPIRATION IN HUMANS | Lukacsko, Alison B. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20030064040-A1 | Compositions and methods for inhibiting eccrine perspiration in humans | LIGHTHOUSE INNOVATIONS, LLC | 2003-04-03 | — | — | US | claimed |
| WO-2003026585-A2 | COMPOSITIONS AND METHODS FOR INHIBITING ECCRINE PERSPIRATION IN HUMANS | LUKACSKO ALISON B (US) | 2003-04-03 | — | — | WO | claimed |
| WO-2000020414-A9 | PIPERIDYLOXADIAZOLES AS DOPAMINE RECEPTOR ANTAGONISTS | COMBICHEM INC (US) | 2002-08-22 | — | — | WO | claimed |
| JP-H09503491-A | — | — | 1997-04-08 | — | — | JP | claimed |
| EP-0314444-B1 | Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments | ISRAEL STATE (IL) | 1996-05-29 | — | — | EP | claimed |
| EP-0711292-A1 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | KOSMIN, Gerald, Emmanuel (GB) | 1996-05-15 | — | — | EP | claimed |
| EP-0303391-B1 | Optical isomers of a spiroquinuclidine derivative | ISRAEL STATE (IL) | 1995-06-07 | — | — | EP | claimed |
| WO-1995003303-A2 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-02-02 | — | — | WO | claimed |
| US-5106831-A | Cholinergic agent | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1992-04-21 | — | — | US | claimed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | claimed |
| US-5053412-A | Central nervous system disorders | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-01 | — | — | US | claimed |
| US-4876260-A | NERVOUS SYSTEM DISORDERS | STATE OF ISRAEL, ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IL) | 1989-10-24 | — | — | US | claimed |
| EP-0314444-A2 | Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-05-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | CHRM2 6/4885BLM 1402/4885PABPC1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.